Ged Gould, Founding Director of HGL Private Capital commented”2024 has been another record year for Futuremeds as it continues to expand its reach and impact in clinical research.
With the opening of a further five new dedicated research sites across Europe and the continued expansion of oncology trial capabilities, Futuremeds is strengthening its position as the leading independent provider of clinical trials in Europe. The growth reflects the trust placed in Futuremeds by both sponsors and patients. Futuremeds is well on track to achieve another record breaking year in 2025.”
Recent Futuremeds success stories:
